Immunovant (IMVT) revenue

There is no revenue history on record here for Immunovant (IMVT). Figures as of 18 Nov 2026, 03:11 UTC, from the company's filings with the SEC and Yahoo Finance.

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Not enough data

A history of revenue needs at least 3 fiscal years; none is on record here for Immunovant. Nothing is estimated to fill the gap.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Immunovant and comparable companies
CompanyRevenueFiscal year
Bausch + Lomb BLCO$5.10B2025
Amneal Pharmaceuticals AMRX$3.02B2025
Caris Life Sciences CAI$812.03M2025
Axsome Therapeutics AXSM$638.50M2025
Chemed CHE$2.53B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IMVT

Immunovant, figure by figure

Immunovant (IMVT) overview: price, valuation and scorecardAll health care companies by market value

Immunovant revenue: questions and answers

How is Immunovant's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Immunovant (IMVT) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/IMVT/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.